Atomo Diagnostics: Enters U.S. partnership for rapid COVID-19 tests

Atomo Diagnostics: Enters U.S. partnership for rapid COVID-19 tests

• Atomo Diagnostics has entered a partnership with U.S. company Access Bio for the commercialisation of rapid COVID-19 antibody tests
• The companies will market two separate tests; one for professional healthcare use and another for home self-testing
• Atomo will receive a percentage of the gross revenues from the sale of the products
• Then the companies anticipate the professional devices will submitted for approval by the end of the year
• Atomo co-founder and CEO, John Kelly, also says the new partnership is an exciting development for the company
• Nearing Tuesday’s close, Atomo Diagnostics is trading 6.8 per cent higher at 39.5 cents